JAK2 and acute lymphoblastic leukemia: How, then, do CRLF2/JAK2 mutant B-ALL cells that depend on mutant JAK2 for disease initiation remain alive and proliferating (albeit more slowly) following sustained pharmacological inhibition or genetic depletion of the driving oncoprotein JAK2?